Direct answer
Sleep-supplement evidence depends on the problem and exact product. Historical melatonin trials support adult jet lag; adult delayed sleep-wake phase disorder has a weak suggestion for clinician-guided timed melatonin. Small trials do not establish a best supplement for chronic insomnia, which has strong support for multicomponent CBT-I. Product labels, medicines, kidney/liver health and funding disclosures matter.
- A historical Cochrane review supports short-term melatonin for adult jet lag. AASM 2015 gives a weak suggestion for strategically timed melatonin in adult delayed sleep-wake phase disorder; this differs from a strong chronic-insomnia treatment (Jet-lag review; Circadian guideline).
- In JAMA testing of 25 US melatonin gummy products, 22 had melatonin outside ±10% of the label. All 5 CBD-containing products declared CBD on their labels; this was a content test, not an efficacy study (Original gummy analysis).
- The 2021 magnesium review searched through October 2020 and included 3 RCTs/151 older adults. Low-to-very-low certainty and mixed endpoints do not establish a best sleep formulation or a current exhaustive trial count (Original review).
- Glycine had selected fatigue/vigilance signals in 7 healthy employees under sleep restriction; it was not a chronic-insomnia trial. L-theanine results are mixed, including null primary outcomes and no subjective-sleep advantage in a 30-person branded-ingredient trial (Glycine human study; GAD trial; AlphaWave trial).
- The reviewed ZMA experiment, homeopathy reports and CBD pilot do not establish broad sleep-product claims. Their limitations differ: an acute young-male study, uncontrolled/fixed-order reports, and a small 2-week CBD trial (ZMA; Case report; Fixed-order study; CBD pilot).
Table of contents
- Evidence summary
- Bottom-line verdict table
- Evidence and funding map
- What sleep supplements can and cannot do
- Selected supplement forms
- Ingredients and clinical evidence
- Popular ingredients and claims with weak evidence
- Selected safety concerns
- Selected interactions and precautions
- When professional assessment matters
- Frequently asked questions
- Sources
Evidence summary
| Claim | Evidence | Primary source | Funding / conflict trace | Strength |
|---|---|---|---|---|
| Melatonin for adult jet lag. | The 2002 review found benefit in 8 of 10 trials, especially 5 or more time zones/eastbound; correctly timed short-term use matters. | Cochrane original summary | Internal support: University of Auckland and UK Cochrane Centre; no external sources of support supplied. Herxheimer declared none; Petrie undertook two included trials. Underlying trial financing and procurement remain unverified. Original review disclosures | Moderate, indication-specific |
| Melatonin for adult chronic insomnia. | AASM 2017 weakly suggests against routine onset/maintenance use, based on limited very-low-certainty evidence; not all formulations/indications proven ineffective. | AASM 2017 guideline | AASM funded; managed author pharmaceutical research/consulting and employment ties disclosed. | Weak recommendation against routine use |
| Melatonin gummy label accuracy. | 25 US products bought 2022: 22 outside ±10% label; detected 74–347% melatonin. All 5 CBD products labelled CBD. One sample/product, not all lots. | JAMA analysis | Authors disclosed public/private grants, royalties, prior supplement litigation and botanical-conference commercial support; study-specific financing not reported. | Strong for tested-sample mismatch |
| Magnesium insomnia evidence. | 2021 review: 3 RCTs/151 older adults, low/very-low certainty; sleep-onset signal but total-sleep result not significant. | Original review | No specific review grant/no conflicts declared; public/academic scholarships acknowledged. Underlying trial financial chains incomplete. | Weak |
| Glycine: human and animal evidence differ. | Seven healthy employees analyzed after 3 g/night during 3 sleep-restricted nights; selected fatigue/vigilance signals, not chronic insomnia. Separate mechanism paper studied rats. | Human study; Rat mechanism | Ajinomoto employee authors; human paper partial public PROBRAIN support despite no-conflict declaration. Rat paper also Ajinomoto funding. Supply payment/amounts unknown. | Insufficient for chronic insomnia |
| Valerian for adult chronic insomnia. | 2006 review had mixed subjective results/publication bias and inconsistent PSG; AASM 2017 weakly suggests against routine use. | Guideline; Historical meta-analysis | Review acknowledged NCCAM grant; complete review COI and included-trial finances not cleared. Guideline author ties disclosed. | Weak |
| Tart-cherry juice pilots. | Fifteen- and 8-person older-adult crossover analyses found selected signals, with important null outcomes; specific juices/2-week periods. | Pigeon pilot; Losso pilot | Pigeon: CherryPharm funded/supplied juice. Losso: Cherry Marketing Institute support/juice and NIH center grants. Amounts/payment agreements unknown. | Weak, product-specific |
| L-theanine sleep findings. | Psychiatric review is not general insomnia evidence; GAD trial anxiety/total ISI null, selected satisfaction/subgroup signals. AlphaWave subjective sleep null. | Review; GAD; AlphaWave | Review declared no funding/COI; GAD FIT-BioCeuticals co-sponsor/author ties; AlphaWave Ethical Naturals funding and company/KGK employee authors. | Weak, mixed |
| Ashwagandha extract sleep findings. | Five RCTs/400 unique adults, 6–12 weeks, different populations/branded extracts; several pooled signals but PSQI/TIB/QoL not clearly improved. | Cheah 2021 review | Review unfunded/no conflicts; one partly manufacturer-supported trial identified. Complete financing/COI/product terms of all five originals not verified. | Weak to Moderate by outcome |
| CBD alone is distinct from THC combinations. | Two-week 150 mg CBD pilot did not improve primary Insomnia Severity Index (ISI) or most self-rated sleep outcomes versus placebo; selected secondary signals do not establish retail efficacy. | Original CBD pilot; Clinical chapter; Companion funding | Main: Cannvalate/Barbara Dicker Brain Sciences Foundation funding, Brains products. Companion reports Brains study funding/products; differing disclosures retained, amounts unknown. | Insufficient for broad insomnia benefit |
| ZMA acute sleep experiment. | 69 young healthy males, adequate dietary Mg/Zn but no serum status test; 2 nights/condition, no sleep-quality/cognitive advantage and less sleep in some comparisons. | Original ZMA study | LJMU internal funds; ZMA explicitly bought from PhD Nutrition, no company link/COI declared. No muscle-recovery endpoint claim. | Insufficient for insomnia; null acute quality result |
Bottom-line verdict table
| Ingredient / claim | Verdict | Studied role / scope | Main caveat |
|---|---|---|---|
| Melatonin | Indication-specific | Historical adult jet-lag benefit; weak adult DSWPD suggestion. | Not a general chronic-insomnia replacement (Jet lag; DSWPD). |
| Magnesium | Weak insomnia evidence | Nutritional deficiency management differs from proving sleep benefit. | Older-adult review does not establish a best form or deficient-subgroup sleep effect (Review; NIH nutrition). |
| Glycine | Insufficient for chronic insomnia | Selected fatigue/vigilance signals in 7 sleep-restricted healthy employees. | Rat mechanism is not direct human clinical efficacy; chronic-insomnia replication is needed (Human study; Rats). |
| Valerian | Weak | Routine adult chronic-insomnia use not supported by 2017 weak recommendation. | Possible alcohol/sedative precautions; not all hops/blends tested (Guideline; NCCIH). |
| Tart-cherry juice | Weak, product-specific | Selected outcomes in small older-adult 2-week pilots. | Industry-supported specific products, not proven all concentrates/powders (Pigeon; Losso). |
| L-theanine | Weak, mixed | GAD total insomnia/anxiety outcomes null; subgroup signals. | Healthy-stress trial subjective sleep null; not established calm-focus therapy (GAD; AlphaWave). |
| Ashwagandha | Weak to Moderate by outcome | Short differing extract/population trials, not all products. | Important pregnancy/liver/thyroid/autoimmune cautions (Review; NCCIH). |
| CBD sleep products | Insufficient for broad benefit | 150 mg 2-week pilot primaryinsomnia outcome null. | Prescription CBD safety and retail products differ; interactions require exact-medicine review (Pilot; Current pharmaceutical label). |
| ZMA | Insufficient for insomnia | Acute young-male quality/cognition results null. | Dietary status was assessed; deficiency blood tests/muscle recovery were not endpoints (Study). |
| Homeopathic remedies | Insufficient | Reviewed case/fixed-order study cannot establish persistent-insomnia efficacy. | Concurrent medicines/order confounding prevent confident causal attribution (Case; Fixed-order study). |
| “Natural Ambien” blends | Equivalence unestablished | The reviewed evidence does not establish zolpidem-equivalent benefit. | No head-to-head comparison of every marketed blend was performed; valerian guidance is ingredient-specific (Valerian recommendation). |
Text version of this infographic
| Evidence role (editorial) | Ingredients or claims | Scope and limitation |
|---|---|---|
| Indication-specific | Melatonin jet lag; clinician-guided adult DSWPD; nutrient deficiency has a separate nutritional role. | Jet-lag evidence and weak circadian recommendation differ (Review; Guideline; NIH). |
| Limited or mixed clinical evidence | Magnesium, glycine, tart-cherry juice, L-theanine and ashwagandha. | Populations, products and endpoints differ; no best-product comparison (Magnesium; Glycine; Cherry; Theanine; Ashwagandha). |
| Broad efficacy unestablished | ZMA, reviewed homeopathy reports, CBD products and Ambien-equivalence claims. | Different limits do not prove every possible product ineffective (ZMA; Homeopathy; CBD; Valerian). |
Evidence and funding map
Research funding at a glance
7 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
| Source | Country / scope | Evidence type | Reported funding / conflicts | Clinical credibility (editorial) | Remaining limits |
|---|---|---|---|---|---|
| Cochrane 2002 jet-lag summary | Adult travel trials | Historical review summary/abstract | University of Auckland/UK Cochrane Centre internal support; no external support supplied. Herxheimer: none; Petrie conducted two included trials. Trial financial chains and product terms remain unverified. Original review disclosures | Moderate, indication-specific | Not a current all-circadian or chronic-insomnia synthesis. |
| AASM 2017 pharmacologic guideline | Adult chronic insomnia | GRADE guideline | AASM-funded; pharmaceutical author research/consulting and AASM employment declared/managed. | Recommendation-specific | Weak melatonin/valerian recommendations, not proof all preparations fail. |
| Magnesium 2021 review | Older-adult studies | Review/meta-analysis | No specific grant/no conflicts declared; academic/public fellowships acknowledged. | Weak | Underlying finance/procurement and newer-trial census incomplete. |
| JAMA 2023 gummy analysis | 25 US products purchased 2022 | Analytical chemistry | Author public/private grants, royalties, supplement litigation and botanical-conference commercial support disclosed; study financing unreported. | Strong for tested-sample mismatch | One sample/product; not efficacy/all-lot safety. |
| Cheah 2021 ashwagandha review | Five trials in India | Review/meta-analysis | Review unfunded/no conflicts; branded extracts and one partly manufacturer-supported trial reported. | Weak to Moderate by outcome | All five original financial chains and product terms unverified. |
| NCCIH sleep guidance | United States/public guidance | Evidence/safety information | NIH public guidance; institution does not clear contributor or cited-trial finances. | Useful for its stated clinical warnings | Not an original product-efficacy trial or financial independence certificate. |
| Narayan 2024 CBD pilot and companion; Companion disclosures | Australia, 30 analyzed | Two reports of one cohort | Main funding Cannvalate/Barbara Dicker Brain Sciences Foundation; Brains supplied treatments. Companion reports Brains study funding/products. Sponsors no reported analytic/publication role. | Insufficient for broad insomnia benefit | Differing funding statements not reconciled; amounts/product terms unknown. |
What sleep supplements can and cannot do
A sleep complaint needs an appropriate assessment before selecting a supplement. Adult chronic insomnia has a strong recommendation for multicomponent CBT-I; snoring, gasping and marked daytime sleepiness warrant discussion of sleep apnea. Jet-lag and delayed sleep-wake phase evidence should not be generalized to every cause of poor sleep. The small ingredient trials below also differ in population, formulation and outcome (AASM 2021 CBT-I; NCCIH assessment; Jet lag; Adult DSWPD).
Selected forms and evidence grades
| Selected form/type | Examples | Studied role | Evidence limitation | Editorial assessment |
|---|---|---|---|---|
| Melatonin | Immediate/prolonged release, liquids, tablets and gummies differ. | Historical jet-lag evidence; weak clinician-guided adult DSWPD recommendation. | No proof every delivery form equally effective; gummy content accuracy is separate. | Indication-specific (Jet lag; DSWPD; Gummy testing). |
| Magnesium | Selected oral salts; products and elemental doses differ. | Nutrition/deficiency management, not automatically insomnia treatment. | ODS solubility information does not establish glycinate/threonate superiority for sleep. | Weak insomnia evidence (NIH; 2021 review). |
| Glycine / L-theanine | Powders/capsules used in specific studies; blends are not equivalent. | Selected small-study signals, mixed theanine results. | Healthy restricted sleepers/GAD adults differ from chronic-insomnia populations. | Insufficient for broad insomnia benefit (Glycine; GAD; AlphaWave). |
| Selected herbal extracts | Valerian and ashwagandha; hops may occur in some valerian mixtures. | Product-specific trials; tradition/mechanisms do not establish efficacy. | Other herbs and every mixture were not systematically verified here. | Weak or outcome-specific (Valerian; Ashwagandha). |
| Tart-cherry juice | Specific Montmorency/apple blend and juice tested. | Two-week older-adult pilot outcomes. | Juice trials do not establish powders/concentrates/kiwi/milk peptides or every tea. | Weak, industry-supported pilots (Pigeon; Losso). |
| CBD versus mixed cannabinoids | CBD-alone 150 mg differs from THC-dominant ZTL101. | Small short trials, different endpoints. | THC/CBN mixture results cannot be assigned to CBD alone or all retail gummies. | Insufficient for broad CBD benefit (CBD; THC-dominant trial). |
| Gummies / blends | Single- and multi-ingredient marketed preparations. | A content test assessed 25 melatonin-gummy products. | 22 had melatonin mismatch; all 5 CBD products labelled CBD. No testing of every blend. | Check exact product rather than assume testing proves benefit (JAMA; NCCIH quality guidance). |
| Homeopathic products | Case remedies and coffee-sensitive volunteer preparations differed. | Reviewed reports cannot establish reliable persistent-insomnia benefit. | No control in case; placebo always earlier in 2010 study; not causal proof of either remedy or placebo. | Insufficient (Case; Fixed-order study). |
Text version of this infographic
- Timing disorders differ: historical adult jet-lag benefit and a weak suggestion for clinician-guided adult DSWPD timing are not universal circadian treatment (Jet lag; DSWPD).
- Magnesium nutritional needs differ from sleep efficacy; the 2021 older-adult review does not establish a best form or low-status subgroup benefit (NIH; Review).
- Glycine/theanine signals do not establish routine stress-arousal or chronic-insomnia treatment (Healthy restricted sleepers; GAD; Healthy stress trial).
- Snoring, gasping or marked daytime sleepiness warrant discussion with a clinician about possible sleep apnea (NCCIH assessment).
Ingredients and clinical evidence
Melatonin: indication and timing matter
The 2002 jet-lag review supports correctly timed short-term use in adults, especially travel across 5 or more time zones. AASM 2015 weakly suggests strategically timed melatonin for adult DSWPD, with low-certainty evidence. AASM 2017 weakly suggests against routine melatonin for adult chronic onset/maintenance insomnia; this does not establish every form/indication as ineffective. Gummies, immediate/prolonged-release products and other routes cannot be assumed equivalent. JAMA’s tested gummy sample had frequent melatonin-label mismatch; all CBD products disclosed CBD on their labels (Jet-lag summary; Circadian guideline; Adult chronic-insomnia guideline; Gummy analysis).
Magnesium: useful mineral, weak sleep pill
NIH ODS says citrate, chloride, lactate and aspartate tend to be better absorbed than oxide/sulfate, but absorption is not proof of superior sleep outcomes. The 2021 review searched through October 2020 and included 3 RCTs/151 older adults, with low/very-low certainty and mixed outcomes. It does not establish glycinate as gentlest, a best sleep salt, universal threonate failure or efficacy of every listed form. Elemental dose, kidney function and exact medicine interactions matter (NIH ODS; Original review).
Glycine: a small sleep-restriction study
The human experiment analyzed 7 healthy male Ajinomoto employees given 3 g/night during 3 nights of sleep restriction in a single-blind crossover. Selected fatigue/vigilance measures improved, but several subjective outcomes were not significant and chronic insomnia was not tested. The separate glycine 2 g/kg mechanism experiment was in rats; its NMDA/SCN findings are not direct human therapeutic proof. Both papers have Ajinomoto employee/funding relationships. Collagen or blends are not the tested pure-glycine regimen (Human study; Rat mechanism).
Tart cherry: food-based but not proven therapy
Pigeon analyzed 15 older adults after 2 weeks of a proprietary Montmorency/apple blend: selected Insomnia Severity Index (ISI) and waking-after-onset signals, but total-sleep/latency/efficiency comparisons were not significant. Losso analyzed 8 older adults after excluding 3 with apnea; polysomnographic (PSG) total-sleep and one questionnaire efficiency signal improved, but ISI and PSG efficiency did not. Both trials had industry support/supplied juice; Losso also acknowledged NIH center grants. These findings do not establish all cherry concentrates/powders or long-term safety (Pigeon; Losso).
L-theanine: mixed sleep findings
The psychiatric-disorder review does not establish general calm-focus or insomnia therapy. In 46 GAD adults receiving stable antidepressants, 450–900 mg L-theanine for 8 weeks did not beat placebo on anxiety or total ISI; satisfaction/subclinical subgroup signals were exploratory evidence. A separate 30-person healthy-stress AlphaWave trial found no subjective-sleep advantage and less actigraphic sleep versus placebo, with baseline imbalance. GAD was FIT-BioCeuticals co-sponsored; AlphaWave had Ethical Naturals funding and company/KGK employee authors (Psychiatric review; GAD abstract/disclosures; AlphaWave original).
Ashwagandha: promising but conflict-sensitive
Cheah 2021 review included 5 RCTs/400 unique adults in India, using branded KSM-66 or Shoden extracts for 6–12 weeks in differing populations. Several pooled outcomes favored extract, but PSQI, TIB and quality-of-life results were not clearly improved; certainty varied low/moderate. The review was unfunded and declared no conflicts, but identified one partly manufacturer-supported trial; all five original financial chains were not verified here. NCCIH warns about short/long-term safety limits, pregnancy/lactation, liver injury, thyroid/autoimmune conditions and possible medicine interactions (Original review; NCCIH).
Text version of this infographic
- Assess each clinical claim by trial design, endpoint, population, precision and direct relevance; an institutional label is not proof of financial independence.
- A small randomized trial can identify a signal while remaining too imprecise or selected to establish routine treatment.
- Funding, employee authors and supplied products require disclosure; sponsorship and methodological quality are separate assessments.
- Case reports, fixed-order experiments and mechanistic claims cannot by themselves establish persistent-insomnia efficacy.
Popular ingredients and claims with weak evidence
ZMA: limited acute trial scope
The acute ZMA study involved 69 young healthy male recreational athletes, prescribed 4 h or 8 h sleep for 2 nights per condition. Diet suggested adequate Mg/Zn intake; serum deficiency was not measured. No quality/cognitive advantage was shown, and some actigraphic sleep measures decreased. LJMU internal funds purchased PhD Nutrition ZMA; no company relationship/conflicts were declared. This experiment does not establish a chronic-insomnia or muscle-recovery verdict for every stack (Original study).
Sleep gummy blends
The 2023 JAMA content test analyzed 25 US melatonin-gummy products bought in 2022, one sample each. Twenty-two were outside ±10% of labelled melatonin; all 5 CBD-containing products labelled CBD, and none had detectable serotonin. This is not an efficacy test or an all-brand/all-lot safety finding. NCCIH cautions that combining products and appealing gummy presentation can create separate safety concerns; keep melatonin away from children (Original analysis; NCCIH melatonin; Product safety).
Homeopathic sleep remedies
The 2024 case had concurrent psychiatric medicines and subsequent changes, with no control group. The 2010 study involved 54 coffee-sensitive college participants, with placebo always preceding remedy; selected PSG changes were accompanied by more awakenings/arousals, while subjective/actigraph results were not clearly improved. These designs cannot establish persistent-insomnia efficacy or prove causal placebo/remedy effects. The 2010 paper disclosed NIH support and Bell’s homeopathic-manufacturer consultancy; supplier Hahnemann pellets were purchased. Persistent insomnia warrants established assessment/care (Case; Fixed-order study; CBT-I guideline).
CBD sleep overclaims
The 150 mg sublingual CBD pilot lasted 2 weeks and analyzed 30 completers. Primary ISI and most self-rated sleep outcomes did not outperform placebo; objective efficiency was a secondary signal, and wellbeing was already higher at baseline. It was not a formal diagnostic clinical-insomnia sample. Walsh’s separate ZTL101 trial used 10–20 mg THC plus 1–2 mg CBN and 0.5–1 mg CBD, not CBD alone; selected ISI/diary/actigraphy benefits came with PSG null results, adverse events and likely unblinding. Main CBD funders were Cannvalate/Barbara Dicker Brain Sciences Foundation, with Brains treatment supply; companion reports Brains study funding. Prescription CBD has defined dose/context-specific liver and medicine risks (CBD original; THC-dominant original; Clinical chapter; Current pharmaceutical label).
Valerian as “natural Ambien”
The reviewed evidence does not establish zolpidem-equivalent valerian or blend efficacy. AASM 2017 weakly suggests against routine valerian in adult chronic onset/maintenance insomnia; low-quality evidence is not proof every preparation ineffective. NCCIH cautions about combining valerian with alcohol/sedatives because sleep-inducing effects are possible. That precaution does not quantify a clinical interaction rate for every herb or mixture (Original guideline; NCCIH valerian).
Selected safety concerns
| Ingredient | Reported effects / evidence limits | Rare but serious concerns | At-risk populations | Source supporting the specific concern |
|---|---|---|---|---|
| Melatonin | Sleepiness, headache, dizziness and nausea reported; older adults may have prolonged daytime effects. | Long-term/pediatric developmental safety remains uncertain; uncertainty is not proven endocrine harm. | Children, pregnancy/lactation or epilepsy/blood-thinner use need professional advice/supervision. | NCCIH |
| Oral magnesium | Diarrhea, nausea and abdominal cramps at high supplemental doses; no sleep-salt tolerability ranking established here. | Excessive intake can cause serious toxicity, especially impaired renal clearance. | Review kidney function, elemental intake from all products and medicine interactions. | NIH ODS |
| Glycine | A dependable adverse-event rate for 3 g bedtime use is not established by the cited high-dose psychiatric abstract. | The 30 g/day clozapine study was preliminary and did not improve symptoms; not a proven 3 g interaction/all-antipsychotic effect. | Discuss exact psychiatric medicines with the prescriber; other pregnancy/organ-specific safety is not established by this source. | Original clozapine abstract |
| Valerian (not every hops/blend product) | Listed headache/GI upset/mental dullness/excitability/uneasiness/vivid dreams; rates not uniform. | Long-term safety uncertain; very rare liver reports usually involve combinations and attribution is difficult. | Possible alcohol/sedative combination risk; pregnancy/lactation data limited. | NCCIH valerian |
| Tested tart-cherry juices | Neither small pilot provides reliable GI/reflux/loose-stool incidence or all-product safety. | Eight-person Losso analysis reported no adverse events, insufficient to exclude uncommon/long-term harm. | Pigeon excluded diabetes/high glucose. Check exact product/diet requirements; specific anticoagulant/glucose/potassium interactions not established. | Pigeon; Losso |
| L-theanine | AlphaWave trial had 2 possibly related mild events: dry mouth and metallic taste; other events largely judged unrelated. | Thirty selected adults/28 days cannot establish uncommon or long-term safety; review populations differ. | Trial excluded sleep/psychiatric disorders and several medicines; no universal BP/sedative/stimulant interaction magnitude established. | Original safety Results; Population-specific review |
| Ashwagandha | Drowsiness, GI upset, diarrhea/vomiting reported; event rates not established for every extract. | Rare clinically apparent liver injury; severe cases especially with preexisting liver disease. | Avoid pregnancy/lactation; not recommended thyroid/autoimmune disease; avoid cirrhosis/advanced liver disease; review possible medicine interactions. | NCCIH; LiverTox |
| CBD; mixed cannabinoids differ | Prescription-dose CBD can cause GI/appetite/sedation effects; retail-dose incidence is not established. THC mixtures are separate exposures. | Dose-related liver-enzyme injury and selected medicine interactions, especially valproate; do not apply epilepsy-trial rates to every gummy. | Exact dose/product/medicines and liver function require clinical review; prescription CBD monitoring is product-specific. | StatPearls; Human toxicity review; Current label |
The original CBD sleep paper names Cannvalate and Barbara Dicker Brain Sciences Foundation as funders and Brains Bioceuticals as treatment supplier. Its companion daytime report instead states Brains study funding/product supply. Both report sponsor noninvolvement in the described scientific/publication roles. These are differing reports of one cohort, not two independent replications; amounts and contractual/product payment terms are unknown (Original disclosure; Companion disclosure).
Selected interactions and precautions
| Ingredient | Interacts with | Mechanism / concern | Precaution / uncertainty (editorial) | Action |
|---|---|---|---|---|
| Melatonin | Other medicines/alcohol and combined sleep products. | Exact combination risks differ; NCCIH advises considering combinations and effects on alertness. | Professional review | Review full ingredients/medicines before combining; do not infer a measured interaction for every sedative class (Melatonin safety; Combination precautions). |
| Melatonin | Blood thinners or epilepsy; other treated conditions need exact-medicine assessment. | NCCIH specifically calls for medical supervision for epilepsy/blood-thinner users. | Medical supervision | No universal glucose/BP/immune/seizure-threshold interaction or class-wide stopping rule is established here (NCCIH). |
| Magnesium | Tetracycline/quinolone antibiotics. | Can complex with the medicine and reduce absorption. | Relevant absorption interaction | Follow exact antibiotic label/prescriber spacing; do not use one interval for every medicine (NIH ODS). |
| Magnesium | Oral bisphosphonates. | Can reduce medicine absorption. | Relevant absorption interaction | Follow exact product fasting/spacing instructions. A universal iron/zinc/calcium/thyroid schedule is not supplied by this source (NIH ODS). |
| Magnesium | Loop/thiazide or potassium-sparing diuretics; long-term PPIs; impaired kidney function. | Directions differ: increased losses versus reduced excretion, possible PPI magnesium depletion and reduced renal clearance. | Exact-medicine / renal review | Discuss status and total intake with the treating team; kidney disease is a condition, not a drug interaction (NIH ODS). |
| Glycine | Clozapine. | Thirty grams/day in 19 schizophrenia patients did not help; possible antagonism was preliminary. | Uncertain low-dose relevance | Do not infer 3 g bedtime or all-antipsychotic interaction. Review proposed use with the psychiatric prescriber (Original abstract). |
| Valerian | Alcohol/sedatives. | Possible sleep-inducing combination effects; exact rates unknown. | Precaution | NCCIH advises avoiding the combination. This does not establish identical hops/blend/opioid interaction rates (NCCIH). |
| L-theanine | Exact medicines/other ingredients. | Reviewed trials do not establish universal antihypertensive/sedative/stimulant interaction effects or monitoring protocols. | Uncertain | Disclose the product/medicines to a clinician; a branded 28-day trial is not a complete interaction screen (AlphaWave; Review). |
| Ashwagandha | Selected diabetes/BP drugs, immunosuppressants, sedatives, anticonvulsants and thyroid medicines. | NCCIH lists possible interactions; magnitude and probability are not uniform or established for every product. | Professional assessment | Follow pregnancy/lactation/thyroid/autoimmune cautions and liver-disease guidance; no generic alcohol/hepatotoxic-drug interaction rate established (NCCIH; LiverTox). |
| CBD | Clinically defined prescription CBD combinations, including clobazam, everolimus and valproate; other substrates require exact review. | Current label: altered selected drug exposure, valproate-associated liver risk, possible additive CNS sedation/alcohol effect. | Prescriber/pharmacist review | These pharmaceutical-dose findings cannot quantify every retail product/medicine pair; do not change medicines yourself (Current official label; Clinical chapter). |
| Tart-cherry juice | Exact medicine/restricted-diet context. | These pilots do not establish anticoagulant, glucose-lowering or potassium-mediated drug-interaction rates. | Unestablished by these studies | Check exact product/nutrition requirements with the treating team; no generic anticoagulant prohibition follows from the pilots (Pigeon; Losso). |
Text version of this infographic
| Risk cluster | Examples | Action |
|---|---|---|
| Combined sleep products | Valerian/alcohol/sedatives; CBD combinations require exact review. | Avoid assuming all combinations safe; follow ingredient-specific warnings (Valerian; CBD label; NCCIH). |
| Medicine absorption | Magnesium with selected antibiotics/oral bisphosphonates. | Follow exact medicine spacing instructions; not a universal all-mineral schedule (NIH ODS). |
| Liver / metabolism concerns | CBD prescription-dose/selected medicines; ashwagandha injury/advanced liver disease. | Professional assessment; not measured additive risk for every alcohol/drug/herb combination (CBD label; Ashwagandha LiverTox). |
When professional assessment matters
Professional assessment is particularly important for children, pregnancy/lactation, persistent insomnia, medicines and kidney/liver conditions. The specific precaution depends on the ingredient: melatonin with epilepsy/blood thinners; magnesium with impaired renal clearance; ashwagandha with pregnancy/thyroid/autoimmune or advanced liver disease; CBD with selected medicines/liver risks. Snoring, gasping or marked daytime sleepiness warrants possible sleep-apnea evaluation. These selected examples are not a complete contraindication list or proof every supplement is unsafe in every listed condition (NCCIH assessment; Melatonin; Magnesium; Ashwagandha; LiverTox; CBD label).
Frequently asked questions
Does evidence depend on the sleep problem?
Yes. Historical melatonin evidence for adult jet lag differs from a weak suggestion for strategically timed melatonin in adult DSWPD. For adult chronic insomnia, AASM strongly recommends multicomponent CBT-I and weakly suggests against routine melatonin in its 2017 drug guideline. This is not an all-products head-to-head ranking (Jet lag; Circadian; CBT-I; Pharmacologic guideline).
Is magnesium good for sleep?
The 2021 review found low/very-low-certainty evidence from 3 RCTs/151 older adults, with a sleep-onset signal but total-sleep result not significant. Correcting nutritional deficiency is a separate role; the review does not prove low-status people obtain insomnia benefit or establish a best formulation (Original review; NIH nutrition).
Does glycine work for sleep?
The cited human study found selected fatigue/vigilance signals in 7 healthy sleep-restricted employees over 3 nights, not reliable chronic-insomnia efficacy. The mechanism paper studied rats, not human 3 g bedtime treatment. Ajinomoto employment/funding relationships matter, and longer independent clinical replication is needed (Human original; Rat original).
Are sleep gummies safe?
Content accuracy and safety are separate from efficacy. JAMA tested 25 US melatonin gummies bought 2022; 22 had melatonin mismatch and all 5 CBD products labelled CBD. One sample/product cannot clear every lot. NCCIH highlights child-access and combination precautions; testing/certification does not itself prove benefit or universal safety (JAMA; Melatonin safety; Quality guidance).
Is valerian a natural Ambien?
The reviewed evidence does not establish zolpidem-equivalent valerian/blend benefit. AASM 2017 weakly suggests against routine adult chronic-insomnia use; NCCIH cautions about possible alcohol/sedative combinations. This is not a head-to-head test of every marketed blend (Guideline; NCCIH).
Does CBD help sleep?
The 2-week 150 mg CBD pilot analyzed 30 people and found no primary ISI or most self-rated sleep advantage; selected secondary signals do not establish broad benefit. Its funding was commercial/charitable as reported, with product supply, and the companion is the same cohort. Prescription CBD has defined medicine/liver risks; retail-dose event rates are not established by those studies (Original pilot; Clinical chapter; Current label).
What did the ZMA sleep experiment find?
In 69 young healthy male recreational athletes, 2-night crossover conditions did not show a sleep-quality or cognitive advantage; some sleep measures decreased. Diet indicated adequate Mg/Zn but serum status was not tested. Muscle recovery and chronic insomnia were not established endpoints, so no universal product verdict follows (Original study).
Are homeopathic sleep remedies evidence-based?
The reviewed case and fixed-order volunteer study cannot establish persistent-insomnia efficacy: concurrent medication changes and placebo-before-remedy order are important confounders. They also do not prove all preparations harmless. Persistent insomnia should receive appropriate evaluation; AASM 2021 supports multicomponent CBT-I for adults (Case; Fixed-order study; CBT-I).
Can I combine multiple sleep supplements?
Combination safety depends on exact ingredients, doses and medicines. NCCIH advises checking risks of combining sleep products; valerian/alcohol or sedatives have a specific precaution, and prescription CBD has defined selected-medicine/liver and possible CNS depressant warnings. A clinician/pharmacist can assess the complete list; no comprehensive interaction screen or universal safe stack is supplied here (NCCIH; Valerian; CBD label).
Sources
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane
- Sateia MJ, et al. AASM pharmacologic treatment guideline for chronic insomnia in adults. PubMed
- NCCIH. Sleep Disorders and Complementary Health Approaches. NCCIH
- Cohen PA, et al. Quantity of Melatonin and CBD in Melatonin Gummies. PMC
- Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults. PMC
- NIH Office of Dietary Supplements. Magnesium Fact Sheet. NIH ODS
- Bannai M, et al. Glycine and sleep-related daytime performance. PMC
- Kawai N, et al. Glycine sleep-promoting and hypothermic effects. PMC
- Bent S, et al. Valerian for sleep: systematic review and meta-analysis. PMC
- NCCIH. Valerian: Usefulness and Safety. NCCIH
- Pigeon WR, et al. Tart cherry juice beverage and sleep in older adults with insomnia. PMC
- Losso JN, et al. Tart cherry juice for insomnia and mechanisms. PMC
- Moshfeghinia R, et al. L-theanine systematic review. PMC
- Sarris J, et al. L-theanine adjunctive trial in generalized anxiety disorder. PubMed
- Cheah KL, et al. Ashwagandha extract and sleep systematic review/meta-analysis. PMC
- NCCIH. Ashwagandha. NCCIH
- LiverTox. Ashwagandha. NCBI Bookshelf
- Narayan AJ, Downey LA, Rose S, Di Natale L, Hayley AC. Cannabidiol for moderate–severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. Journal of Clinical Sleep Medicine. 2024;20(5):753–763. Original sleep trial
- Walsh JH, et al. Cannabinoid medicine for chronic insomnia symptoms. PMC
- StatPearls. Cannabidiol in Clinical Care. NCBI Bookshelf
- CBD metabolism and liver toxicity review. PMC
- ZMA acute sleep study. PMC
- Homeopathic insomnia case report. PMC
- Homeopathic medicines and polysomnographic sleep. PMC
- Auger et al. AASM 2015 circadian guideline — adult DSWPD sections; Edinger et al. AASM 2021 adult behavioral-insomnia guideline; Epidiolex prescribing information, revised May 2026
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.